Table of Contents
International Journal of Molecular Imaging
Volume 2014, Article ID 471032, 5 pages
http://dx.doi.org/10.1155/2014/471032
Research Article

Comparison of 99mTc-Tetrofosmin and 99mTc-Sestamibi Uptake in Glioma Cell Lines: The Role of P-Glycoprotein Expression

1Neurosurgical Institute, University of Ioannina, Stavros Niarchos Avenue, 45500 Ioannina, Greece
2Department of Nuclear Medicine, University Hospital of Ioannina, Stavros Niarchos Avenue, 45500 Ioannina, Greece
3Department of Medical Physics, University of Ioannina, Stavros Niarchos Avenue, 45500 Ioannina, Greece

Received 19 July 2014; Accepted 17 October 2014; Published 10 November 2014

Academic Editor: Seigo Kinuya

Copyright © 2014 George A. Alexiou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Schillaci, A. Spanu, and G. Madeddu, “[99mTc]sestamibi and [99mTc]tetrofosmin in oncology: SPET and fusion imaging in lung cancer, malignant lymphomas and brain tumors,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. 2, pp. 133–144, 2005. View at Google Scholar · View at Scopus
  2. J. Y. Choi, S. E. Kim, H. J. Shin, B.-T. Kim, and J. H. Kim, “Brain tumor imaging with 99mTc-tetrofosmin: comparison with 201Tl, 99mTc-MIBI, and 18F-fluorodeoxyglucose,” Journal of Neuro-Oncology, vol. 46, no. 1, pp. 63–70, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. F. P. Le Jeune, F. Dubois, S. Blond, and M. Steinling, “Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies,” Journal of Neuro-Oncology, vol. 77, no. 2, pp. 177–183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. G. A. Alexiou, A. D. Fotopoulos, A. Papadopoulos, A. P. Kyritsis, K. S. Polyzoidis, and S. Tsiouris, “Evaluation of brain tumor recurrence by 99mTc-tetrofosmin SPECT: a prospective pilot study,” Annals of Nuclear Medicine, vol. 21, no. 5, pp. 293–298, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Minutoli, F. F. Angileri, S. Cosentino et al., “99mTc-MIBI SPECT in distinguishing neoplastic from nonneoplastic intracerebral hematoma,” Journal of Nuclear Medicine, vol. 44, no. 10, pp. 1566–1573, 2003. View at Google Scholar · View at Scopus
  6. S. Nagamachi, S. Jinnouchi, K. Nabeshima et al., “The correlation between 99mTc-MIBI uptake and MIB-1 as a nuclear proliferation marker in glioma—a comparative study with 201TI,” Neuroradiology, vol. 43, no. 12, pp. 1023–1030, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. G. A. Alexiou, S. Tsiouris, A. P. Kyritsis et al., “The value of 99mTc-tetrofosmin brain SPECT in predicting survival in patients with glioblastoma multiforme,” Journal of Nuclear Medicine, vol. 51, no. 12, pp. 1923–1926, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Le Jeune, N. Perek, D. Denoyer, and F. Dubois, “Influence of glutathione depletion on plasma membrane cholesterol esterification and on Tc-99m-sestamibi and Tc-99m-tetrofosmin uptakes: a comparative study in sensitive U-87-MG and multidrug-resistant MRP1 human glioma cells,” Cancer Biotherapy and Radiopharmaceuticals, vol. 19, no. 4, pp. 411–421, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Le Jeune, N. Perek, D. Denoyer, and F. Dubois, “Study of monoglutathionyl conjugates TC-99M-sestamibi and TC-99M-tetrofosmin transport mediated by the multidrug resistance-associated protein isoform 1 in glioma cells,” Cancer Biotherapy & Radiopharmaceuticals, vol. 20, no. 3, pp. 249–259, 2005. View at Publisher · View at Google Scholar
  10. G. A. Alexiou, A. Goussia, A. P. Kyritsis et al., “Influence of glioma's multidrug resistance phenotype on 99mTc-tetrofosmin uptake,” Molecular Imaging and Biology, vol. 13, no. 2, pp. 348–351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. E. Stacy, P. J. Jansson, and D. R. Richardson, “Molecular pharmacology of ABCG2 and its role in chemoresistance,” Molecular Pharmacology, vol. 84, no. 5, pp. 655–669, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. K. I. Tsamis, G. A. Alexiou, E. Vartholomatos, and A. P. Kyritsis, “Combination treatment for glioblastoma cells with tumor necrosis factor-related apoptosis-inducing ligand and oncolytic adenovirus delta-24,” Cancer Investigation, vol. 31, no. 9, pp. 630–638, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. G. D. Luker, T. P. Flagg, Q. Sha et al., “MDR1 P-glycoprotein reduces influx of substrates without affecting membrane potential,” Journal of Biological Chemistry, vol. 276, no. 52, pp. 49053–49060, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Kinuya, J. Bai, K. Shiba et al., “99mTc-sestamibi to monitor treatment with antisense oligodeoxynucleotide complementary to MRP mRNA in human breast cancer cells,” Annals of Nuclear Medicine, vol. 20, no. 1, pp. 29–34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Fukumoto, “Single-photon agents for tumor imaging: 201Tl, 99mTc-MIBI, and 99mTc-tetrofosmin,” Annals of Nuclear Medicine, vol. 18, no. 2, pp. 79–95, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Spiegl-Kreinecker, J. Buchroithner, L. Elbling et al., “Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes,” Journal of Neuro-Oncology, vol. 57, no. 1, pp. 27–36, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. D. S. Tews, C. Fleissner, B. Tiziani, and A. K. A. Gaumann, “Intrinsic expression of drug resistance-associated factors in meningiomas,” Applied Immunohistochemistry and Molecular Morphology, vol. 9, no. 3, pp. 242–249, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Demeule, A. Régina, J. Jodoin et al., “Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier,” Vascular Pharmacology, vol. 38, no. 6, pp. 339–348, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Bronger, J. König, K. Kopplow et al., “ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier,” Cancer Research, vol. 65, no. 24, pp. 11419–11428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. C.-T. Kuan, K. Wakiya, J. E. Herndon II et al., “MRP3: a molecular target for human glioblastoma multiforme immunotherapy,” BMC Cancer, vol. 10, article 468, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Perek, F. Koumanov, D. Denoyer, D. Boudard, and F. Dubois, “Modulation of the multidrug resistance of glioma by glutathione levels depletion—interaction with TC-99M-Sestamibi and TC-99M-Tetrofosmin,” Cancer Biotherapy and Radiopharmaceuticals, vol. 17, no. 3, pp. 291–302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Kolchinsky and I. B. Roninson, “Drug resistance conferred by MDR1 expression in spheroids formed by glioblastoma cell lines,” Anticancer Research, vol. 17, no. 5 A, pp. 3321–3327, 1997. View at Google Scholar · View at Scopus